Showing results (71-80 of 210) with videos related to

Sort By:
Pageof 21
Blood Cancer Journal|February 7, 2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug developmentPralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Blood Cancer Journal|March 11, 2020
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysisMeletios A Dimopoulos, Ruben Niesvizky, Katja Weisel, et al.
Lancet (London, England)|July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 studyMeletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Frontiers in Immunology|November 17, 2022
CD38-specific nanobodies allow <i>in vivo</i> imaging of multiple myeloma under daratumumab therapyLuca Julius Pape, Julia Hambach, Anna Josephine Gebhardt, et al.
The Lancet. Oncology|June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyPhilippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Hemasphere|March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 TrialKatja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
MDM Policy & Practice|February 8, 2019
Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision MakingSebastian Gonzalez-McQuire, Meletios-Athanassios Dimopoulos, Katja Weisel, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
Pageof 21